Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities

Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US$69 million follow-on public offering of equity securities

Press releases | 26 January 2024

Houston, Philadelphia, 26, January 2024 – Global law firm Hogan Lovells advised Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) (“Perspective”) on a series of strategic transactions with Lantheus Holdings (NASDAQ: LNTH), which consisted of a $20.8 million private placement of shares of Perspective’s common stock, Perspective’s grant to Lantheus of options to negotiate an exclusive license and/or co-develop certain of Perspective’s therapeutic candidates, and Perspective’s agreement to acquire Lantheus’ Somerset, New Jersey manufacturing facility and related assets.

Hogan Lovells also advised Perspective on its US$69 million follow-on public offering of (i) 156,399,542 shares of its common stock at the public offering price of $0.37 per share and (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 30,086,944 shares of its common stock at a price of $0.369 per pre-funded warrant. Oppenheimer & Co. and B. Riley Securities acted as joint book-running managers for the public offering.

More information about the strategic transactions with Lantheus and the follow-on public offering of equity securities can be found here and here.

Perspective Therapeutics is a clinical-stage radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope Lead-212 to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

The Hogan Lovells team was led by partners Andrew Strong (Houston) and Stephen Nicolai (Philadelphia), with assistance from partners Cullen Taylor (Northern Virginia), Lynn Mehler (Washington, D.C.), Carin Carithers (Washington, D.C.), Scott Reisch (Denver), Steve Abrams (Philadelphia), Steven Schneider (Washington, D.C), Steven Kaufman (Washington, D.C.), Nancy O'Neil (Baltimore), senior counsel Henry Kahn (Baltimore), counsel Eric Andalman (Denver), counsel Ted Lis (Washington, D.C.), senior associates Amanda Brown (Philadelphia), Daniel Garcia (Houston), Matthew Miller (Denver), Naadia Chowdhury (New York), Zachary Siegel (Philadelphia), Elizabeth Adams (Washington, D.C), Sally Gu (Washington, D.C.), Wil Henderson (Denver), associates Kayvon Paul (Philadelphia), Swati Parashar (Houston), Tyler Glass (Philadelphia), Will Tenbarge (Washington, D.C.) and paralegal coordinator Leyla Gungor (Washington, D.C.).